Notable launches Patient AI, the world’s first use of large language models and GPT to bring personalization at scale to healthcare
Notable, the leading intelligent automation company for healthcare, launched Patient AI, the world’s first use of large language models (LLMs) and GPT (the technology powering ChatGPT) to bring personalization at scale to healthcare. Patient AI continuously reviews millions of data points across medical records and third-party data sets to develop a comprehensive clinical and social understanding of each patient. These insights are automatically translated into personalized recommendations that are surfaced to the patient before, after, and in between encounters through adaptive design without any staff involvement. The result is that patients are engaged at precisely the right moment to take action in achieving their health goals.
As consumers, we have highly personalized experiences across retail, financial services, entertainment, and other aspects of our lives, and yet the healthcare experience has remained decidedly impersonal. This is despite the fact that trillions of dollars have been spent working to shift healthcare from what was a very analog industry to one that is far more digital. It is estimated that healthcare today accounts for a whopping 30% of the world’s data volume. Yet, capitalizing on that data to personalize the patient experience and improve care has remained elusive for most health systems. The labor-intensive nature of mining, reading, and drawing conclusions from these data sets, combined with staffing shortages, has made it infeasible to personalize care for all patients. The result is fragmented, delayed, or deferred care, leading to poor outcomes for patients and inhibited revenue growth for health systems.
“The entire industry is talking about generative AI and ChatGPT,” said Pranay Kapadia, Chief Executive Officer and Co-Founder of Notable. “While others talk, we’ve been busy incorporating LLMs into our intelligent automation platform and the early results are incredibly encouraging. From the very beginning, we’ve embraced an iterative deployment methodology that allows us to capitalize on the rapid pace at which technology continues to evolve. Going forward, we are committed to safely deploying Patient AI into all of our digital assistant solutions to allow caregivers to practice at the top of their license.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more